Order Article Reprints

Tse BC, Said BI, Fan ZJ, Hueniken K, Patel D, Gill G, Liang M, Razooqi M, Brown MC, Sacher AG, et al. Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment. Current Oncology. 2020; 27(6):552-559. https://doi.org/10.3747/co.27.6563

Tse, B.C., B.I. Said, Z.J. Fan, K. Hueniken, D. Patel, G. Gill, M. Liang, M. Razooqi, M.C. Brown, A.G. Sacher, and et al. 2020. "Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment" Current Oncology 27, no. 6: 552-559. https://doi.org/10.3747/co.27.6563

Tse, B. C., Said, B. I., Fan, Z. J., Hueniken, K., Patel, D., Gill, G., Liang, M., Razooqi, M., Brown, M. C., Sacher, A. G., Bradbury, P. A., Shepherd, F. A., Leighl, N. B., Xu, W., Howell, D., Liu, G., & O’Kane, G. (2020). Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment. Current Oncology, 27(6), 552-559. https://doi.org/10.3747/co.27.6563